Open-label pilot study of extended-release naltrexone to reduce drinking and driving among repeat offenders

Journal of Addiction Medicine

Volumn 5, Issue 3, 2011, Pages 163-169

  Lapham, Sandra C ^a   McMillan, Garnett P ^a  

^a PACIFIC INSTITUTE FOR RESEARCH AND EVALUATION   (United States)

Author keywords

Alcohol dependence treatment; DUI; DWI; Impaired driving; Naltrexone

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; NALTREXONE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREATH ANALYSIS; CLINICAL ARTICLE; CONTROLLED RELEASE FORMULATION; DRINKING BEHAVIOR; DRUNKEN DRIVING; EXTENDED RELEASE SUSPENSION; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HELP SEEKING BEHAVIOR; HUMAN; MALE; MEAN CORPUSCULAR VOLUME; OFFENDER; OPEN STUDY; PILOT STUDY; SELF REPORT; SEX DIFFERENCE; SUSPENSION; TREATMENT OUTCOME;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; AUTOMOBILE DRIVING; BIOLOGICAL MARKERS; BREATH TESTS; CRIMINALS; DELAYED-ACTION PREPARATIONS; FEASIBILITY STUDIES; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; PILOT PROJECTS; PROTECTIVE DEVICES; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052717054     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e3181eb3b89     Document Type: Article

References (33)

1. Abraham AJ. The early adoption of Vivitrol: Preliminary data from the National Treatment Center Study Private Sector Study. Abstract of poster presented at Addiction Health Services Research Conference, Athens, GA, October 2007.
2. Beirness DJ, Simpson HM, Mayhew DR. Programs and policies for reducing alcohol-related motor vehicle deaths and injuries. Contemp Drug Probl 1998;25:553.
3. De Young DJ. An evaluation of the effectiveness of alcohol treatment, driver license actions and jail terms in reducing drunk driving recidivism in California. Addiction 1997;92:989-997.
4. Dill PL, Wells-Parker E. Court-mandated treatment for convicted drinking drivers. Alcohol Res Health 2006;29:41-48. (Pubitemid 44944822)
5. Driving Laws.org. United States DUI Laws, DWI laws in New Mexico. 2010. Available at: http://dui.drivinglaws.org/nmexico.php. Accessed May 18, 2010.
6. Dunbar JL, Turncliff RZ, Dong Q, et al. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res 2006;30:480-490. (Pubitemid 43341354)
7. Fell J. Current trends: drivers with repeat convictions or arrests for driving while impaired-United States. Morb Mortal Wkly Rep 1994;43:759-761.
8. Fell JC. Repeat DWI offenders in the United States. 85, 1-4. 1995. Washington, DC: National Highway Traffic Safety Administration. Traffic tech: Technology transfer series. Available at: http://www.nhtsa.dot.gov/people/ outreach/traftech/1995/TT085 .htm. Accessed November 30, 2009.
9. Fell JC, Klein TM. Update: Alcohol-related traffic fatalities, United States, 1982-1993. Morb Mortal Wkly Rep 1994;43:861-867.
10. Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 1999;23:1289-1295. (Pubitemid 29409341)
11. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. J Am Med Assoc 2005;293:1617-1625. (Pubitemid 40471792)
12. Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: A review of the evidence. J Am Med Assoc 1999;281:1318-1325. (Pubitemid 29174484)
13. Harris KM, DeVries A, Dimidjian K. Trends in naltrexone use among members of a large private health plan. Psychiatr Serv 2004;55:221. (Pubitemid 38298804)
14. Hermos JA, Young MM, Gagnon DR, et al. Patterns of dispensed disulfiram and naltrexone for alcoholism treatment in a veteran patient population. Alcohol Clin Exp Res 2004;28:1229-1235. (Pubitemid 39108621)
15. Lapham S, Forman R, Alexander M, et al. The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients. J SubstAbuse Treat 2009;36:1-6.
16. Lapham SC, C'de Baca J, Kapitula LR, et al. Psychiatric disorders in a sample of repeat impaired-driving offenders. J Stud Alcohol 2006;64:707-713. (Pubitemid 44162729)
17. Lapham SC, Skipper BJ, Simpson GL. A prospective study of the utility of standardized instruments in predicting recidivism among first DWI offenders. J Stud Alcohol 1997;58:524-530. (Pubitemid 27344175)
18. Lapham SC, Smith E, C'de Baca J, et al. Prevalence of psychiatric disorders among persons convicted of driving while impaired. Arch Gen Psychiatry 2001;58:943-949. (Pubitemid 32937916)
19. Marques PR, Tippetts AS, Voas RB. Comparative and joint prediction of DUI recidivism from alcohol ignition interlock and driver records. J Stud Alcohol 2003;64:83-105.
20. NHTSA. State Legislative Fact Sheet: Repeat intoxicated driver laws. 2000. Available at: http://www.nhtsa.gov/people/outreach/safesobr/21qp/html/ fact-sheets/Repeat-Intox-Driver.html.Accessed December 22, 2009
21. Nochajski TH, Stasiewicz PR. Relapse to driving under the influence (DUI): A review. Clin Psychol Rev 2006;26:179-195. (Pubitemid 43238387)
22. O'Malley SS, Garbutt JC, Gastfriend DR, et al. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol 2007;27:507-512. (Pubitemid 47415052)
23. Pettinati HM, Weiss RD, Dundon W, et al. A structured approach to medical management: A psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol Suppl 2005;15:170-178. (Pubitemid 41193192)
24. Pettinati HM, Weiss RD, Miller WR, et al. Medical Management Treatment Manual. Vol 2, NIH Pub No. 04-5289. COMBINE Monograph Series. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism;2004
25. Pristach EA, Nochajski TH, Wieczorek WF, et al. Psychiatric symptoms and DWI offenders. Alcohol Alcohol Suppl 1991;1:493-496.
26. Rosenbloom DL. Holidays, triggers, and willpower-Is there a role for medications? A commentary on "The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients." J Subst Abuse Treat 2009;36:7.
27. SAMHSA. Naltrexone and alcohol treatment. Treatment improvement protocol (TIP) series 28. (SMA) 98-3206, 1130-1135. 1998. Rockville, MD: U.S. Department of Health and Human Services. Available at: http://ncadi.samhsa.gov/govpubs/ BKD268/28c.aspx. Accessed December 22, 2009.
28. Sobell LC, Sobell MB. Timeline follow-back: A technique for assessing selfreported ethanol consumption. In: Litten RZ, Allen JP, eds. Measuring alcohol consumption: Psychosocial and biochemical methods. Totowa, NJ: The Humana Press Inc.; 2007:41-72.
29. Solnick SJ, Hemenway D. Hit the bottle and run: The role of alcohol in hit-and-run pedestrian fatalities. J Stud Alcohol 1994;55:679-684. (Pubitemid 24356270)
30. Stephenson JJ, Montejano L, Wang S, et al. Predictors of oral naltrexone adherence in an insured population in the USA. Poster presented at American Academy of Addiction Psychiatry 2006 Annual Meeting. St. Pete Beach, FL, December 7-10, 2006.
31. U.S. Department of Transportation, National Highway Traffic Safety Administration. Traffic Safety Facts: Fatalities related to alcohol-impaired driving during the Christmas and New Year's Day holiday periods. 2007.Washington, DC: NHTSA's National Center for Statistics and Analysis. Available at: http://www-nrd.nhtsa.dot.gov/Pubs/810870.PDF. AccessedOctober 30, 2009.
32. Volpicelli JR, Pettinati HM, McLellan AT, et al. Combining medication and psychosocial treatments for addictions: The BRENDA approach. New York, NY: The Guilford Press; 2001.
33. Wieczorek WF, Callahan CP, Miller BA. Victimization experiences and problem drinking among DWI offenders. Alcohol Clin Exp Res 1994; 18:475.